Autonomic dysreflexia: Current pharmacologic management.
Ryan Solinsky
PMID 37545115WHAT IT FOUND
Nitroglycerin ointment was the initial medication for autonomic dysreflexia in 82% of 60 surveyed physicians, but it was not used in Canada or Latin America where availability was limited.
Nifedipine, captopril, amlodipine, or carvedilol were used there.
Key findings
01Nitroglycerin ointment was the first-line medication for autonomic dysreflexia in 82% of surveyed physicians, including 49 of 50 US physicians.
02Among 10 surveyed physicians from Canada or Latin America, none used nitroglycerin ointment, and all but one said it was no longer available; first-line choices were nifedipine (5), captopril (3), amlodipine (1), or carvedilol (1).
03Sixty-seven percent of physicians had explicit second-line medications; among them, hydralazine (48%) and nifedipine (28%) were most common.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The survey reports physicians' prescribing patterns, not patient outcomes, so it does not show which medication is best or safest. Only 60 physicians responded, and only 10 were from Canada or Latin America, so the findings may not represent all regions or settings. Physicians were recruited through a meeting and network contacts, not a random sample, and SCI subspecialty training was not required. The study did not collect data on how often autonomic dysreflexia occurred or what happened after treatment.
Declared interests
The supplied text does not include an author conflict-of-interest statement. The article is listed as receiving NIH extramural research support.
The easy way to misread this
Do not read this as evidence that nitroglycerin ointment is the best or safest medication for autonomic dysreflexia. It reports physicians' prescribing patterns, not patient outcomes, and the sample was small and geographically limited.